 GSK PLC LSE:GSK, NYSE:GSK shares fell despite a double dose of positive news, with the EU medical regulator accepting its application for a myelofibrosis treatment and success in a Phase-3 endometrial cancer trial. The European Medicines Agency EMA validated the marketing authorisation application for momelotinib, the FTSE 100-listed drugmakers potential new oral treatment for myelofibrosis, a rare blood cancer. 